Get the Stockscreener App
83.78
5.29%
4.21
After Hours:
83.80
0.02
+0.02%
Monopar Therapeutics Inc stock is traded at $83.78, with a volume of 107.03K.
It is up +5.29% in the last 24 hours and down -28.73% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
See More
Previous Close:
$79.57
Open:
$78.28
24h Volume:
107.03K
Relative Volume:
0.50
Market Cap:
$562.35M
Revenue:
-
Net Income/Loss:
$-14.99M
P/E Ratio:
-40.54
EPS:
-2.0665
Net Cash Flow:
$-10.01M
1W Performance:
+5.16%
1M Performance:
-28.73%
6M Performance:
+56.28%
1Y Performance:
-14.96%
1-Day Range:
$77.98
$85.03
1-Week Range:
$75.33
$85.03
52-Week Range:
$50.07
$124.82
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
83.78 | 572.11M | 0 | -14.99M | -10.01M | -2.0665 |
VRTX
Vertex Pharmaceuticals Inc
|
505.64 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
196.48 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
742.12 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
928.44 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
200.87 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | Morgan Stanley | Overweight |
| Nov-14-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-25 | Initiated | Leerink Partners | Outperform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Aug-26-25 | Resumed | H.C. Wainwright | Buy |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
Form 144 MONOPAR THERAPEUTICS INC For: 1 October By Investing.com - Investing.com Canada
16,800 shares are proposed for sale by Monopar Therapeutics (MNPR) director Christopher Starr. - Stock Titan
Form 4 insider transaction filed pressures Monopar Therapeutics stock below $74.23 support - Traders Union
Form 4 Monopar Therapeutics Inc For: 28 September By Investing.com - Investing.com Nigeria
Monopar Therapeutics CEO Robinson sells $2.5m in stock By Investing.com - Investing.com Canada
Four share sales at $87.15 to $89.79: Monopar Therapeutics (MNPR) CEO also exercised options. - Stock Titan
(MNPR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Monopar Therapeutics stock price prediction: Support pressure looms at $81.33 - Traders Union
Form 144 MONOPAR THERAPEUTICS INC. For: 25 September By Investing.com - Investing.com Nigeria
Stock-option shares are proposed for sale by Chandler Robinson at Monopar Therapeutics (NASDAQ: MNPR). - Stock Titan
Monopar Therapeutics stock falls 7.5 percent on September 23 - AD HOC NEWS
Monopar Therapeutics shares drop more than 7% after stock trades below short-term moving averages - Traders Union
Why is Monopar Therapeutics stock down today? Key support levels to watch - Traders Union
Monopar Therapeutics stock trades on a clinical pipeline catalyst - AD HOC NEWS
H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $125 - Moomoo
Monopar Therapeutics Inc (1IY0.MU) Analyst insights, Price targets and RecommendationsYahoo Finance - Yahoo Finance Singapore
Monopar Therapeutics stock trades quietly as investors weigh recent trial and funding updates - AD HOC NEWS
Monopar Therapeutics Inc.(NasdaqCM:MNPR) added to S&P Biotechnology Select Industry Index - marketscreener.com
MNPR slides nearly 5% as technical indicators confirm continued short-term weakness - Traders Union
Monopar Therapeutics stock trades near $92.46 support amid ongoing pullback - Traders Union
Monopar Therapeutics stock forecast: Selloff remains in focus - Traders Union
Monopar Therapeutics Is Maintained at Overweight by Barclays - Moomoo
MNPR Maintained by Barclays -- Price Target Raised to $145 - GuruFocus
Barclays Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $145 - Moomoo
Discipline and Rules-Based Execution in MNPR Response - Stock Traders Daily
Monopar Therapeutics shares technical analysis: $120.21 resistance in focus after rally - Traders Union
Monopar Therapeutics stock trades near record levels as investors react to insider selling and stron - AD HOC NEWS
What's behind Monopar Therapeutics's latest 3.0% stock pullback? - Traders Union
MNPR Q2 2026 Earnings: Narrower-Than-Expected Loss of $0.62 Highlights Clinical-Stage DisciplineEPS Miss Report - dars.gov.et
Monopar Therapeutics director Kim Tsuchimoto sells $455,566 in shares By Investing.com - Investing.com Canada
Monopar Therapeutics (MNPR) director sells 4,090 shares after option exercises - Stock Titan
Monopar Therapeutics director Raymond Anderson sells $351,835 in stock By Investing.com - Investing.com Canada
Monopar (MNPR) insider sells at $110–113 after $30 option exercise - Stock Titan
Will Monopar Therapeutics stock regain momentum as oversold conditions limit further selling? - Traders Union
Monopar director Kim Tsuchimoto sells $455k in common stock By Investing.com - Investing.com Nigeria
Monopar Therapeutics director Raymond Anderson sells $351k in stock By Investing.com - Investing.com Canada
Monopar Therapeutics Director Kim R. Tsuchimoto Executes Six-Tranche Stock Sale Under Rule 10b5-1 Plan - Kalkine Media
Monopar Therapeutics (MNPR) CMO uses plan to exercise options - Stock Titan
Monopar Therapeutics director Raymond Anderson sells USD 349,125 of common shares - Bitget
Monopar Therapeutics (MNPR) director sells 3,142 shares in plan trade - Stock Titan
Monopar Therapeutics (MNPR) director plans $906K share sale - Stock Titan
Monopar Therapeutics stock resistance test: Key levels to watch - tradersunion.com
Monopar (NASDAQ: MNPR) director to sell 6,284 shares - Stock Titan
Companies Like Monopar Therapeutics (NASDAQ:MNPR) Can Afford To Invest In Growth - webull.com
Monopar (MNPR) Quarter in Focus: EPS Clears the Reported Estimate in the Current Update; Trading Response: Shares Close 2.85% Lower in the Latest SessionForward EPS Estimate - vinanet.vn
Monopar (MNPR) Latest: Ends Lower by 2.85% at $107.72 in the Latest Reading; Technical Setup: Price Remains Between $102.33 Support and $113.11 Resistance at the CloseBreak of Structure - vinanet.vn
MNPR drops as short-term selling pressure persists - Traders Union
Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $130 - Moomoo
What's behind Monopar Therapeutics's latest stock pullback? - Traders Union
Monopar (MNPR) Chart: Retreats 2.41% to $120.85 in the Latest Reading; Price Levels: $114.81 and $126.89 Define the Nearby Reference Levels under the Current SnapshotLeveraged ETF Flow - vinanet.vn
Monopar (MNPR) Earnings Report: EPS Beats Its Estimate for the Current Session; Session Move: The Stock Ends Up 4.02% in the Latest ReadingInterim Report - vinanet.vn
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Monopar Therapeutics Inc Stock (MNPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| STARR CHRISTOPHER M | Director |
Oct 01 '26 |
Sale |
78.50 |
8,400 |
659,387 |
5,173 |
0.50%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):